Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MSB-CAR001 + hyaluronan is an investigational combination therapy evaluated for intra-articular injection following anterior cruciate ligament (ACL) reconstruction. The therapy consists of two components: MSB-CAR001, which is a preparation of mesenchymal precursor cells (MPCs), and hyaluronan, a naturally occurring glycosaminoglycan used as a viscosupplement to restore synovial fluid properties in the joint. The combination aims to enhance joint healing and recovery by leveraging the regenerative potential of MPCs together with the lubricating and shock-absorbing properties of hyaluronan. Clinical studies have focused on assessing safety and preliminary efficacy in patients post-ACL reconstruction[1][2][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MSB-CAR001 + hyaluronan.